Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiol Therapeutics Inc T.CRDL.W.A


Primary Symbol: T.CRDL Alternate Symbol(s):  CRDL

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive... see more

Recent & Breaking News (TSX:CRDL)

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Newsfile March 7, 2023

Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis

TheNewsWire January 17, 2023

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Newsfile January 17, 2023

Why Investors Should Buy Into this Company Targeting Heart Diseases … Now

Jocelyn Aspa December 20, 2022

Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

TheNewsWire December 16, 2022

Cardiol (TSX:CRDL) begins heart disease drug trials

Caroline Egan  December 12, 2022

Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Newsfile December 12, 2022

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Newsfile November 14, 2022

CardiolRx study demonstrates ‘protective effects’ vs. acute pericarditis

Jeff Nielson November 9, 2022

Cardiol Therapeutics (TSX:CRDL) discovers protective effects of CardiolRX

Brieanna McCutcheon  November 7, 2022

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis

Newsfile November 7, 2022

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Newsfile October 25, 2022

Cardiol Therapeutics (TSX: CRDL) announces CardiolRx pre-clinical study results

John Ballem  October 3, 2022

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Newsfile October 3, 2022

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Newsfile September 28, 2022

60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago

Accesswire September 27, 2022

Is this company the next GW Pharma? Phase II study now underway

Jeff Nielson August 8, 2022

Cardiol Therapeutics (TSX:CRDL) reports first patient enrolled in Phase Il clinical trial for acute myocarditis treatment

Dave Jackson August 3, 2022

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis

Newsfile August 3, 2022

A medical play developing CBD-based treatments for cardiovascular diseases

Jonathon Brown July 13, 2022